CN1282470C - Traditional Chinese medicine for anti depression - Google Patents
Traditional Chinese medicine for anti depression Download PDFInfo
- Publication number
- CN1282470C CN1282470C CN 200510055375 CN200510055375A CN1282470C CN 1282470 C CN1282470 C CN 1282470C CN 200510055375 CN200510055375 CN 200510055375 CN 200510055375 A CN200510055375 A CN 200510055375A CN 1282470 C CN1282470 C CN 1282470C
- Authority
- CN
- China
- Prior art keywords
- radix
- preparation
- chinese medicine
- group
- fructus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 85
- 238000002360 preparation method Methods 0.000 claims abstract description 48
- 241000208966 Polygala Species 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 119
- 239000000706 filtrate Substances 0.000 claims description 33
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 24
- 239000000843 powder Substances 0.000 claims description 24
- 239000000796 flavoring agent Substances 0.000 claims description 23
- 238000004064 recycling Methods 0.000 claims description 22
- 235000019634 flavors Nutrition 0.000 claims description 21
- 239000007788 liquid Substances 0.000 claims description 19
- 239000000243 solution Substances 0.000 claims description 14
- 238000010992 reflux Methods 0.000 claims description 13
- 230000001430 anti-depressive effect Effects 0.000 claims description 12
- -1 filtered Substances 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 238000002481 ethanol extraction Methods 0.000 claims description 11
- 235000019640 taste Nutrition 0.000 claims description 11
- 239000007921 spray Substances 0.000 claims description 10
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 9
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 9
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 9
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 9
- 239000000935 antidepressant agent Substances 0.000 claims description 8
- 229940005513 antidepressants Drugs 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 8
- 239000012141 concentrate Substances 0.000 claims description 7
- 239000002994 raw material Substances 0.000 claims description 7
- 239000002674 ointment Substances 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 239000000470 constituent Substances 0.000 claims description 2
- 239000006196 drop Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 3
- 235000013399 edible fruits Nutrition 0.000 abstract 2
- 240000007185 Albizia julibrissin Species 0.000 abstract 1
- 244000131360 Morinda citrifolia Species 0.000 abstract 1
- 235000008898 Morinda citrifolia Nutrition 0.000 abstract 1
- 235000008248 Morinda citrifolia var citrifolia Nutrition 0.000 abstract 1
- 244000236658 Paeonia lactiflora Species 0.000 abstract 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract 1
- 240000006079 Schisandra chinensis Species 0.000 abstract 1
- 235000008422 Schisandra chinensis Nutrition 0.000 abstract 1
- 241001533104 Tribulus terrestris Species 0.000 abstract 1
- IWBJJCOKGLUQIZ-HQKKAZOISA-N hyperforin Chemical compound OC1=C(CC=C(C)C)C(=O)[C@@]2(CC=C(C)C)C[C@H](CC=C(C)C)[C@](CCC=C(C)C)(C)[C@]1(C(=O)C(C)C)C2=O IWBJJCOKGLUQIZ-HQKKAZOISA-N 0.000 abstract 1
- 235000017524 noni Nutrition 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 60
- 229940079593 drug Drugs 0.000 description 25
- 238000012360 testing method Methods 0.000 description 22
- 230000000694 effects Effects 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 19
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 241000700159 Rattus Species 0.000 description 16
- 201000010099 disease Diseases 0.000 description 16
- 210000004185 liver Anatomy 0.000 description 16
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 15
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 14
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 14
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 14
- 229960003147 reserpine Drugs 0.000 description 14
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 14
- 239000003826 tablet Substances 0.000 description 13
- 239000008280 blood Substances 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- 208000020401 Depressive disease Diseases 0.000 description 11
- 230000037396 body weight Effects 0.000 description 11
- 239000001768 carboxy methyl cellulose Substances 0.000 description 11
- 230000000994 depressogenic effect Effects 0.000 description 11
- 210000003734 kidney Anatomy 0.000 description 11
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 10
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 10
- 235000014347 soups Nutrition 0.000 description 10
- 239000000463 material Substances 0.000 description 9
- 230000009182 swimming Effects 0.000 description 9
- 230000002567 autonomic effect Effects 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 208000004130 Blepharoptosis Diseases 0.000 description 7
- 206010015995 Eyelid ptosis Diseases 0.000 description 7
- 239000013543 active substance Substances 0.000 description 7
- 230000003203 everyday effect Effects 0.000 description 7
- 230000002496 gastric effect Effects 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- 201000003004 ptosis Diseases 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 6
- 230000006399 behavior Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 208000024714 major depressive disease Diseases 0.000 description 6
- 206010025482 malaise Diseases 0.000 description 6
- 201000003995 melancholia Diseases 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- KFYRPLNVJVHZGT-UHFFFAOYSA-N Amitriptyline hydrochloride Chemical compound Cl.C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KFYRPLNVJVHZGT-UHFFFAOYSA-N 0.000 description 5
- 241000628997 Flos Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 238000000692 Student's t-test Methods 0.000 description 5
- 229960005119 amitriptyline hydrochloride Drugs 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 206010022437 insomnia Diseases 0.000 description 5
- 238000010998 test method Methods 0.000 description 5
- 238000012449 Kunming mouse Methods 0.000 description 4
- 229960000836 amitriptyline Drugs 0.000 description 4
- 230000036760 body temperature Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 235000008504 concentrate Nutrition 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 230000008451 emotion Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000000582 semen Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010010144 Completed suicide Diseases 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 3
- 208000031975 Yang Deficiency Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 206010003549 asthenia Diseases 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000004356 Hysteria Diseases 0.000 description 2
- 241000581650 Ivesia Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102000010909 Monoamine Oxidase Human genes 0.000 description 2
- 108010062431 Monoamine oxidase Proteins 0.000 description 2
- 241000736199 Paeonia Species 0.000 description 2
- 235000006484 Paeonia officinalis Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229940126678 chinese medicines Drugs 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 208000012839 conversion disease Diseases 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000003001 depressive effect Effects 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 239000009432 erxian tang Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 238000007667 floating Methods 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 229960004644 moclobemide Drugs 0.000 description 2
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000017194 Affective disease Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 101100136092 Drosophila melanogaster peng gene Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 240000008669 Hedera helix Species 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229940087098 Oxidase inhibitor Drugs 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 206010041954 Starvation Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000002153 concerted effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 239000008912 dachengqi decoction Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000010135 fructus aurantii immaturus Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 239000009428 kamisyoyo san Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- ZAVXXBAIPSQJGS-UHFFFAOYSA-B tetracalcium;tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O.[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O.[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ZAVXXBAIPSQJGS-UHFFFAOYSA-B 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- OYPPVKRFBIWMSX-SXGWCWSVSA-N zimeldine Chemical compound C=1C=CN=CC=1C(=C/CN(C)C)\C1=CC=C(Br)C=C1 OYPPVKRFBIWMSX-SXGWCWSVSA-N 0.000 description 1
Abstract
The present invention relates to a traditional Chinese medicine preparation for preventing depression, which is prepared from white peony root, hyperforine, acanthopanax root, schisandra fruit, silktree albizzia bark, polygala root, medicinal indianmulberry root, puncturevine caltrop fruit, etc.
Description
Technical field:
The present invention relates to a kind of antidepressant Chinese medicine preparation, the particularly Chinese medicine preparation made from Chinese medicines such as the Radix Paeoniae Alba, Herba Hyperici Monogyni, Radix Et Caulis Acanthopanacis Senticosi, Fructus Schisandrae Chinensis, Cortex Albiziae, Radix Polygalae, Radix Morindae Officinalis, Fructus Tribulis.
Background technology:
Depression is a kind of commonly encountered diseases frequently-occurring disease, mainly show as feel depressed, energy goes down, pessimism, mild depression be oneself feel that mood is low, grievance, indifferent to, appetite descends and insomnia, is reluctant activity, mental retardation, appearance be can't see obviously unusual mostly.Belong to depressed is the dysthymic disorder of core symptom.Because this depressed and common people are running on the downhearted gloomy surface of short-term that bad mental stimulates the back to occur there is not what difference, allow many people depression be produced a period of time the illusion of " take things too hard or petty " easily.In fact, as long as one has depressive emotion to continue for two weeks or more than two weeks, simultaneously with any four in following nine symptoms, and depressive emotion do not cause by other disease, is exactly typical depression.Nine symptoms are: 1, hebetude or do not have happy sense; 2, energy goes down or continued absence; 3, the movable minimizing or the action sluggishness; 4, undue self-accusation or compunction; 5, association's difficulty or attention can not be concentrated; Idea of 6, committing suicide repeatedly or behavior; 7, insomnia or early awakening; 8, body weight reduces or appetite decline; 9, libido descends.
Incidence: the interrelated data statistics, the depression sickness rate is between 3～20%, some areas are up to more than 25%.And because most patients does not remove hospital admission, therefore, actual sickness rate may be higher.70% be that depression causes in the suicide according to statistics, in the U.S. because of the 10th of the depression suicide row cause of death.Though press statistics, the depression sickness rate of China is lower, and actual sickness rate is not low, and along with the continuous aggravation of social change, competition is fierce more, and depression will be paid attention to by people more and more.
Antidepressant generally is divided into: 1, central stimulants, and as uncommon propylamine.2, oxidase inhibitor is as moclobemide.3, two lopps are as Zelmid.4, tricyclic antidepressants is as imipramine.5, new tricyclic antidepressants is as Clomipramine.6, Fourth Ring class is replaced woods as wheat.From the fifties, the application of tricyclic antidepressant has obtained favorable effects, but significant side reaction is restricted its use.Along with to the pathogenetic continuous understanding of depression, the emphasis of research mainly is in recent years: 1, selectivity 5-HT cell reabsorption inhibitor, and as fluoxetine.2, reversibility monoamine oxidase, MAO two types are selected inhibitor, as moclobemide.In a word, the research of antidepressants is made significant progress, but still have with a certain distance from clinical demand.The relapse rate height of outstanding behaviours after treatment, two aspects of erious adverse reaction.
Chinese medical theory is thought: depression be with continue depressed, mood is smooth, disappointed, pessimistic, interest blank or forfeiture etc. are a kind of syndrome of principal character.Belong to emotion (mental state) obstacle class disease.It is generally acknowledged that depression is equivalent to " melancholia ", " insomnia ", " inferior Die ", " heaving a deep sigh " " dirty dry " " strongly fragrant disease " " feelings will strongly fragrant " disease categories such as " melancholy " of the traditional Chinese medical science more.In fact, the scope of the melancholia that the traditional Chinese medical science is traditional is bigger, has comprised multiple situations such as gas, blood, food, fire, wet, expectorant, and present depression belongs to ancient Chinese medicine said " feelings will strongly fragrant " more.From the core symptom such as depressed grade of modern depression, seemingly more close with clinical manifestations such as traditional Chinese medical science ancient times said " inferior Die ", " dirty dry ".Therefore, can not be because of " melancholia " character express of present " depression " and the traditional Chinese medical science close and both are equal to.Chinese medicine is thought, the generation of depression, be mostly because of disgruntled, ponder over, grief, worried damaged by excess of seven emotions causes the liver failing to maintain the normal flow of QI, spleen loses fortuneization, brain god is not normal, the internal organs yin and yang qi and blood disorder forms, the nervus cardiacus mistake is foster, the QI-insufficiency of Yuanyang hair growth promoting causes.Said as " the strongly fragrant sick opinion in silver-colored straits index south ": as for feelings will is strongly fragrant, here then has three.One angry strongly fragrant, and just it is arrogant, and flushed complexion sound is gone through, and sees abdominal distention more, and after the anger, contrary gas is flat, and middle gas is injured, sees abdominal distention pain more, the disease that asthenia is eaten less.Thought strongly fragrantly on the 1st, all hearts are recalled and business to some extent, and meaning has affiliated and gives birth to and think, and think to have not accomplishedly to form strongly fragrantly, tie in heart person and must hinder, and both very in spleen, on connect the lung stomach, connect Liver and kidney down.Melancholy on the one, or tired or because of terrible leading because of basic necessities of life is collected together eyebrow all day and is caused strongly fragrant person, and the will meaning is well-behaved to be disobeyed, the look rope that disappears, and heart spleen gradually causes consumption hinders, and QI and blood day disappears, and diet day is few, and muscle day disappears, and satisfies to sending out to be a day malaria.Right five gas strongly fragrant, due to illness and Yu Zheye; Feelings will strongly fragrant, because of strongly fragrant patient also.Because disgruntled not smooth, make the liver losing its smoothly moving state, gas loses to dredge and stagnates, so that depression of liver-QI.So the traditional Chinese medical science thinks: " strongly fragrant disease does not have not impairing the liver person yet ... ".Depression of liver-QI, functional activity of QI being not smooth, if fullness and distention in the chest and hypochondrium then stagnation of liver-QI and spleen, is perhaps pondered over and is caused dysfunction of the spleen in transportation, inappetence, insufficiency of vital energy and blood, then the mind is become homeless fosterly, therefore, occurs feeling oneself inferior, and is nervous, and insomnia, lethargy are depressed.If pathogenic fire derived from stagnation of liver-QI, injure cloudy blood, kidney extractum hepatis anemia void then, asthenia of essence and blood, then the brains inanition does not have the many power of light strength certainly, and cross its degree certainly, and the soreness of the shank dizziness occurs, vertigo and tinnitus, order does not have finding, the disease of slack peacefully sleeping and malaise.As seen, though the depression majority has stagnation of QI due to depression of the liver concurrently, depression is not to be exactly simple stagnation of liver-QI, nor is all to be to be main pathogenesis with stagnation of QI due to depression of the liver in all stages of depression, and in treatment, soothing liver-QI for relieving depression is treated merely certainly.Said as " Jing Yue's complete work feelings will strongly fragrant ": as, should to open if just sick and depressed for stagnating the person, suitable suitable; Prolonged illness and undermine in the gas person, should repair, should mend.So with the feelings patient, non-feelings are not understood.It must be willing to then then can release the woman, or contains think of with anger, also can separate temporarily.It is the man, make non-have be able to stoop or to stand, legibility is not eventually to take things philosophically the sage.If disease is existing, damage must very be cut down and go to disappear again, and it is not clear also very.Again if melancholy patient then belongs to fire void, this nothing domination of pathogen entirely.These are many with tired, terrible the leading of basic necessities of life, and sad melancholy is terrified and cause strongly fragrant person, always all are subjected to strongly fragrant and so on.Lid excessive sorrow leading to consumption of QI melancholy then gas is heavy, must impairment of the spleen lung, and excessive fright leading to disturbance of QI, excessive fear leading to sinking of kidney-QI must the impairing the liver kidney.This its sad long, vital essence but the rope of disappearing is arranged, mind is depressed, heart spleen day hinders with consumption.All this generations, all sun disappears card also, but the domination of pathogen still? make and do not know to cultivate vital qi, and add dismission again.
Modern clinical research finds, though depression does not resemble the said whole deficiency syndrome that are of Zhang Jingyue, also is not all to be simple Liver depression and Qi stagnation, and more be deficiency and excess and see that promptly rise at the beginning of the disease, feelings will is hindered, depression of liver-QI is hindered at edema caused by disorder of QI, many excess syndromes based on stagnation of QI due to depression of the liver, it is not smooth that clinical manifestation mostly is depression, lassitude, hypochondriac pain uncomfortable in chest, sighing frequently, anorexia, treatment can be based on the depressed liver-energy dispersing and QI regulating resolving depression, but most of patients is when being diagnosed as depression, often ill a period of time, especially China also is not very high to the awareness of this product now, early stage majority is by insomnia, neurasthenia or do not do any treatment often has not been the initial stage of falling ill when beginning to seek medical advice, in addition, also have a large amount of patients relevant with personality from little formation, therefore, also form gradually, therefore, during the beginning diagnoses and treatment, most of depressions had both had the performance of stagnation of QI due to depression of the liver, also had the Liver and kidney deficiency of YIN-blood, the true QI-insufficiency of Yuanyang in the kidney, the insufficiency of vital energy and blood of more having the inclination, the factor of lack of preservation of spirit.So in treatment, should take into account above several aspect, should liver and kidney tonifying cloudy blood, benefiting QI and nourishing blood again, soothing liver-QI for relieving depression, the tranquilizing by nourishing the heart sedate, Yuanyang in the tonification kidney, middle asthenic fire also will clear away heart-fire.We are through the clinical discovery that studies for a long period of time, and the depression majority is the Liver and kidney deficiency of YIN-blood, and irritability and stagnation of QI due to depression of the liver are simultaneously for suffering from.
Chinese medicine depression present situation: because the depression sickness rate continues to increase, therefore, the treatment of depression more and more causes people's attention, simultaneously because the clinical practice Western medicine the has had certain side effects limit clinical practice of medicine, and Chinese medicine is because to the depression special effect, clinical practice increases gradually, and its clinical trial curative effect is also paid attention to by people gradually, and the method for application Chinese medicine depression accounts for the over half for the treatment of depression.
Clinical report from domestic application Chinese medicine depression, it mainly is compound Chinese medicinal preparation, wherein existing ancient times name side, also with good grounds clinical experience is from the prescription of group, as: Radix Bupleuri adds Os Draconis Concha Ostreae soup, the strongly fragrant refreshing peace soup, five that disappears is spent Chinese herbaceous peonies grass soup, lilii and Rehmanniae Decoction, GANMAI DAZAO TANG, ERXIAN TANG, DACHENGQI TANG, little Radix Bupleuri 9 soup etc.Though anti-anxiety compound has become the field of relatively being paid close attention to, research at present mainly concentrates on clinically, and is very few to its effectiveness and Its Mechanisms report.
GANMAI DAZAO TANG: GANMAI DAZAO TANG is published in Chinese Zhang Zhongjing " Medical Treasures of the Golden Chamber " and cures mainly woman hysteria's disease, Han Zhongbo, Ding Wenjuan etc. obtain satisfactory effect with GANMAI DAZAO TANG treatment depression, total effectively the treatment reaches 845, and think hysteria with separate the depressive illness that also belongs to modern medicine.Ma Yunzhi adopts Shu Yu regulation of mental activities soup (Radix Bupleuri, Radix Curcumae, Rhizoma Acori Graminei, Fructus Aurantii Immaturus, Semen Persicae, Flos Carthami, Semen Platycladi, Radix Polygalae, DUANLONGMU, Radix Salviae Miltiorrhizae) treatment apoplexy retarded depression disease 128 examples, judges curative effect through the HMAD scoring, cures 50 examples; Produce effects 39 examples; Effective 27 examples; Invalid 12 examples, total effective rate are 90.6%.The main effect that reaches simultaneous phenomenon has clear improvement.Zhao Zhisheng adopts self-control to press down to consider recovering capsule (Lignum Aquilariae Resinatum, the Radix Aucklandiae, Fructus Citri Sarcodactylis, Rhizoma Dioscoreae, Rhizoma Acori Graminei, Calculus Bovis, Cinnabaris, succinum, Radix Curcumae, Radix Bupleuri, Semen Ziziphi Spinosae, Radix Polygalae) every day 3 times, each 6,30 days courses of treatment, observation is to anxiety, depressed curative effect, wherein depressed treatment group 30 examples of fully recovering, produce effects 7 examples, 4 examples that take a turn for the better, total effective rate 91.1% cures 66.7%; Matched group (amitriptyline) recovery from illness 16 examples, produce effects 7 examples, 13 examples that take a turn for the better, invalid 9 examples, total effective rate 80%, cure rate 35.6%.The treatment group is controlled the rate of fullying recover from an illness and is significantly higher than matched group (P＜0.01).Peng Fazhong treats depressive state 40 examples with the collaborative low dose of tricyclics of resolving depression soup (Radix Bupleuri, Rhizoma Cyperi (processed), Radix Glycyrrhizae Preparata, the Radix Paeoniae Alba, Semen Ziziphi Spinosae, Radix Curcumae, Radix Angelicae Sinensis, Poria cum Radix Pini, QINGLONGCHI, Rhizoma Acori Graminei, Fructus Jujubae, Chen Xiaomai), cure 25 examples, show into 13 examples, progressive 1 example, total effective rate is 97.5%, the author thinks that side effect is in little than singly proving effective soon with tricyclics simultaneously.The pestle deep pool is clear all obtains healing with Didang Wan treatment two example delay depression of sex.Guo Jianjun force adds flavor treatment depression 64 examples with ERXIAN TANG, cures 22 examples, 38 examples that take a turn for the better, and invalid 4 examples, aggregate efficiency is 93%.Resolving depression soup II: Liu's treasured is employed resolving depression soup (Radix Bupleuri, the Radix Paeoniae Alba, Poria, the Rhizoma Atractylodis Macrocephalae, Radix Codonopsis, Pericarpium Citri Reticulatae, the Radix Astragali, Radix Curcumae, Rhizoma Cyperi, Semen Ziziphi Spinosae, Radix Glycyrrhizae) treatment masked deptession disease (masked depression) 31 examples, cure 15 examples, produce effects 8 examples, 5 examples take a turn for the better, invalid 3 examples, total effective rate are 90%.Zhang Liangdong treats 26 routine affective psychosis with JIAWEI XIAOYAO SAN, treatment 8 week back marked improvement 16 examples, and progressive 7 examples, invalid 3 imitate example.10 routine hypochondriacal plasma cAMP content are found not only to be lower than the normal person after measured, also are lower than schizophrenia, and the cAMP of inclined to one side yang deficiency is lower than inclined to one side yang deficiency person among the melancholia, and wherein there were significant differences for the cAMP content before and after the inclined to one side yang deficiency patient of 5 examples.Dong Junfeng cures 39 examples, 9 examples that take a turn for the better, invalid 2 examples, total effective rate 96% with strongly fragrant refreshing peace soup (Radix Bupleuri, the Radix Paeoniae Alba, Semen Ziziphi Spinosae, Poria, Fructus Schisandrae Chinensis, the Rhizoma Anemarrhenae, Radix Angelicae Sinensis, Caulis Polygoni Multiflori) treatment melancholia 50 examples that disappear.Guo Zhifeng treats melancholia 136 examples with five flower Chinese herbaceous peony grass soup, this side be late old docter of TCM Changchun Wei, Zhejiang Prov. Hospital of Traditional Chinese Medicine through proved recipe, by Flos Rosae Rugosae, Flos Citri Sarcodactylis, FLOS MUME, Flos Semen Lablab Album, Flos Magnoliae Officinalis, the Radix Paeoniae Alba, Radix Glycyrrhizae Preparata are formed, take medicine 10 doses, produce effects 32 examples, effective 89 examples, invalid 15 examples, total effective rate 88.97%.
Antidepressant Chinese patent medicine in the market is few, and existing medicine belongs to a bit cures the symptoms, not the disease, and some uses expensive composition, and some is cut and interrupt using owing to uncertain therapeutic efficacy in application process.
The invention provides a kind of determined curative effect, safe ready, little, the cheap pure traditional Chinese compound medicine of side effect.
Summary of the invention:
The invention provides a kind of antidepressant Chinese medicine preparation, said preparation is made by Chinese medicines such as the Radix Paeoniae Alba, Herba Hyperici Monogyni, Radix Et Caulis Acanthopanacis Senticosi, Fructus Schisandrae Chinensis, Cortex Albiziae, Radix Polygalae, Radix Morindae Officinalis, Fructus Tribulis.
Chinese medicine preparation of the present invention, prescription is made of monarch drug 8 herbal medicines: the Radix Paeoniae Alba, ministerial drug: Herba Hyperici Monogyni, Radix Et Caulis Acanthopanacis Senticosi, adjuvant drug: Fructus Schisandrae Chinensis, Cortex Albiziae, Radix Polygalae, Radix Morindae Officinalis, Fructus Tribuli.
Chinese medicine preparation of the present invention has the cloudy blood of liver and kidney tonifying, benefiting QI and nourishing blood again, soothing liver-QI for relieving depression, tranquilizing by nourishing the heart sedate, Yuanyang in the tonification kidney, and the middle asthenic fire that clears away heart-fire.All medicines are made a concerted effort, and have played liver and kidney tonifying, the effect of resolving stagnation for tranquilization.
Chinese medicine preparation of the present invention, its prescription is composed as follows:
Radix Paeoniae Alba 286-1144 part Herba Hyperici Monogyni 286-1144 part Radix Et Caulis Acanthopanacis Senticosi 179-715 part Fructus Schisandrae Chinensis 179-715 part
Cortex Albiziae 179-715 part Radix Polygalae 179-715 part Radix Morindae Officinalis 179-715 part Fructus Tribuli 179-715 part
Preferred prescription is composed as follows:
Radix Paeoniae Alba 429-763 part Herba Hyperici Monogyni 429-763 part Radix Et Caulis Acanthopanacis Senticosi 268-477 part Fructus Schisandrae Chinensis 268-477 part
Cortex Albiziae 268-477 part Radix Polygalae 268-477 part Radix Morindae Officinalis 268-477 part Fructus Tribuli 268-477 part
Most preferred prescription is composed as follows:
357.5 parts of 357.5 parts of Fructus Schisandrae Chinensis of 572 parts of Radix Et Caulis Acanthopanacis Senticosis of 572 parts of Herba Hyperici Monogynis of the Radix Paeoniae Alba
357.5 parts of 357.5 portions of Fructus Tribulis of 357.5 parts of Radix Morindae Officinaliss of 357.5 parts of Radix Polygalaes of Cortex Albiziae
In more than forming, part is a weight portion, weight is calculated with crude drug, and every part if be unit with the gram, more than forms to can be made into 1000 doses of pharmaceutical preparatioies, described 1000 doses of fingers, the final drug preparation of making, as make 1000 of capsule preparations, 1000 in tablet, granule 1000 grams, oral liquid 1000ml etc.
Can make different Packing Units as granule, as 0.5 gram-5 gram/bags.
More than form, as if being unit with the gram, can be made into the preparation of 50-1000 taking dose, as tablet, make 1000, each taking dose can be the 1-20 sheet, can take 50-1000 time altogether.As granule, make 125 bags, take the 1-2 bag at every turn, can take 62.5-125 time altogether.
More than form to be by weight as proportioning, when producing, can increase or reduce according to corresponding proportion, as large-scale production can be unit with the kilogram, or be unit with the ton, small-scale production can be unit with the milligram also, weight can increase or reduce, but the constant rate of the raw medicinal herbs weight proportion between each composition.
The ratio of above weight proportion obtains through science screening, for especial patient, and as serious symptom or light disease, fat or modest patient, the proportioning of the amount of can corresponding adjustment forming increases or reduces being no more than 100%, and drug effect is constant.
Single medicinal material, especially ministerial drug and adjuvant drug in more than forming also can be replaced by the suitable Chinese medicine with identical property of medicine, and its drug effect of the Chinese medicine preparation after the replacement is constant.
Chinese medicine preparation of the present invention is to process through extraction or other modes by the raw material of Chinese medicine that above-mentioned prescription is formed, and makes pharmaceutically active substance, subsequently, with this material is raw material, adds the medicine acceptable carrier when needing, and makes according to the routine techniques of galenic pharmacy.Described active substance can obtain by extracting raw material of Chinese medicine respectively, also can obtain by the co-extracted raw material of Chinese medicine, also can obtain by other modes, as: by pulverize, squeeze, calcine, grind, sieve, percolation, extraction, water are carried, alcohol extraction, ester are carried, methods such as ketone is carried, chromatography obtain, these active substances can be the material of extractum form, can be that dry extract also can be a fluid extract, make different concentration according to the different needs decision of preparation.
Pharmaceutically active substance in the Chinese medicine preparation of the present invention, its shared percentage by weight in preparation can be 0.1-99.9%, all the other are the medicine acceptable carrier.Pharmaceutical preparation of the present invention exists with unit dosage form, and described unit dosage form is meant the unit of preparation, as every of tablet, and capsular every capsules, every bottle of oral liquid, every bag of granule etc.
Chinese medicine preparation of the present invention can be any pharmaceutically useful dosage form, and these dosage forms comprise: tablet, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, oral liquid, suck agent, granule, electuary, pill, powder, unguentum, sublimed preparation, suspensoid, powder, solution, injection, suppository, ointment, plaster, cream, spray, drop, patch.Preparation of the present invention, peroral dosage form preferably, as: capsule, tablet, oral liquid, granule, pill, powder, sublimed preparation, unguentum etc.Capsule most preferably.
Chinese medicine preparation of the present invention, the preparation of its oral administration can contain excipient commonly used, such as binding agent, filler, diluent, tablet agent, lubricant, disintegrating agent, coloring agent, flavoring agent and wetting agent, can carry out coating to tablet in case of necessity.
The filler that is suitable for comprises cellulose, mannitol, lactose and other similar filler.Suitable disintegrating agent comprises starch, polyvinylpyrrolidone and starch derivatives, for example sodium starch glycollate.Suitable lubricant comprises, for example magnesium stearate.The acceptable wetting agent of appropriate drug comprises sodium lauryl sulphate.
Can fill by mixing, the method that tabletting etc. are commonly used prepares solid oral composition.Mix repeatedly active substance is distributed in those compositionss of a large amount of filleies of whole use.
The form of oral liquid for example can be aqueous or oily suspensions, solution, Emulsion, syrup or elixir, perhaps can be a kind of available water before use or other suitable composite dry products of carrier.This liquid preparation can contain conventional additive, such as suspending agent, for example sorbitol, syrup, methylcellulose, gelatin, hydroxyethyl-cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenation edible fat, emulsifying agent, for example lecithin, anhydro sorbitol monooleate or arabic gum; Non-aqueous carrier (they can comprise edible oil), for example almond oil, fractionated coconut oil, such as oily ester, propylene glycol or the ethanol of the ester of glycerol; Antiseptic, for example para hydroxybenzene methyl ester or propyl p-hydroxybenzoate or sorbic acid, and if desired, can contain conventional flavouring agent or coloring agent.
For injection, the liquid unit dosage forms of preparation contains active substance of the present invention and sterile carrier.According to carrier and concentration, this chemical compound can be suspended or dissolving.The preparation of solution is normally by being dissolved in active substance in a kind of carrier filter-sterilized before it is packed into a kind of suitable bottle or ampoule, sealing then.For example a kind of local anesthetic of adjuvant, antiseptic and buffer agent also can be dissolved in this carrier.In order to improve its stability, can be after the bottle of packing into that this compositions is freezing, and under vacuum, water is removed.
Chinese medicine preparation of the present invention, when being prepared into medicament, optionally add suitable medicine acceptable carrier, described medicine acceptable carrier is selected from: mannitol, sorbitol, sodium pyrosulfite, sodium sulfite, sodium thiosulfate, cysteine hydrochloride, TGA, methionine, vitamin C, the EDTA disodium, EDTA calcium sodium, the alkali-metal carbonate of monovalence, acetate, phosphate or its aqueous solution, hydrochloric acid, acetic acid, sulphuric acid, phosphoric acid, aminoacid, sodium chloride, potassium chloride, sodium lactate, xylitol, maltose, glucose, fructose, dextran, glycine, starch, sucrose, lactose, mannitol, silicon derivative, cellulose and derivant thereof, alginate, gelatin, polyvinylpyrrolidone, glycerol, soil temperature 80, agar, calcium carbonate, calcium bicarbonate, surfactant, Polyethylene Glycol, cyclodextrin, beta-schardinger dextrin-, the phospholipid material, Kaolin, Pulvis Talci, calcium stearate, magnesium stearate etc.
Preparation of the present invention is determined usage and dosage according to patient's situation in use, but obeys every day three times, each 1-20 agent, as: 1-20 bag or grain or sheet.
Chinese medicine preparation of the present invention can prepare by the following method.
More than eight flavors, Herba Hyperici Monogyni, Radix Et Caulis Acanthopanacis Senticosi, Fructus Schisandrae Chinensis three flavors add alcohol reflux, extracting solution filters, filtrate recycling ethanol concentrates; The medicinal residues and the Radix Paeoniae Alba, Cortex Albiziae, Radix Polygalae, Radix Morindae Officinalis, the Fructus Tribuli five tastes decoct with water decocting liquid and filter, filtrate concentrates, add ethanol, standing over night filters filtrate recycling ethanol, merge with above-mentioned ethanol extraction concentrated solution, concentrate, obtain active constituents of medicine, this composition is mixed and made into Chinese medicine preparation of the present invention separately or with the medicine acceptable carrier.
For capsule preparations, specifically can adopt following method preparation:
More than eight flavors, Herba Hyperici Monogyni, Radix Et Caulis Acanthopanacis Senticosi, Fructus Schisandrae Chinensis three flavors add 6 times of amount 65% alcohol reflux secondaries, each 2 hours, merge extractive liquid, filtered, filtrate recycling ethanol is concentrated into relative density 1.10～1.12 (60 ℃); The medicinal residues and the Radix Paeoniae Alba, Cortex Albiziae, Radix Polygalae, Radix Morindae Officinalis, the Fructus Tribuli five tastes add 6 times of water gagings and decoct 2 times, and each 2 hours, collecting decoction, filter, filtrate is concentrated into relative density 1.20～1.22 (60 ℃), adds ethanol and makes and contain the alcohol amount and reach 50%, standing over night filters filtrate recycling ethanol, merge with above-mentioned ethanol extraction concentrated solution, be concentrated into relative density 1.10～1.12 (60 ℃), the adding microcrystalline Cellulose is an amount of, be spray dried to fine powder, sieve, incapsulate, make 1000, promptly.
Below data by experiment illustrate beneficial effect of the present invention.
Effect experiment:
Adopt the medicine of the present invention of preferred formulation to carry out effect experiment, be called " Yushu Jiaonang " one in the experiment, the influence of outstanding tail test mice " disappointment " and " motionless " behavior.
Test objective:
Observe the influence of medicine of the present invention to the outstanding tail test mice dead time.
Test material:
Medicine: Yushu Jiaonang extract dry powder (9.35g crude drug/g dry powder), positive element medicine technology development center provides during sky, Beijing, lot number 20021211, it is standby to be made into the suspension of desired concn with 0.5% sodium carboxymethyl cellulose during use; Amitriptyline hydrochloride tablet (25mg), Hunan Dongting Pharmaceutical Co., Ltd., lot number 020125, it is standby to be made into the suspension of desired concn with 0.5% sodium carboxymethyl cellulose during use.
Animal: Kunming mouse (secondary), body weight 18-22g, male, the effluent north laboratory animal department of the Chinese Academy of Sciences of medical university provides, and the quality certification number is 04056.
Test method:
Mice is divided into 5 groups at random, every group 10, be respectively matched group, Yushu Jiaonang low dose group (0.3g/kg, be equivalent to 5 times of the clinical consumption of people), dosage group (0.6g/kg in the Yushu Jiaonang, be equivalent to 10 times of the clinical consumption of people), Yushu Jiaonang high dose group (1.2g/kg, be equivalent to 20 times of the clinical consumption of people) and positive drug amitriptyline group (14mg/kg is equivalent to 10 times of the clinical consumption of people).Administration group gastric infusion every day once, capacity is the 0.2ml/10g body weight, matched group waits the capacity distilled water, successive administration 20 days, administration in the 19th day is after 30 minutes, with reference to Soubrie etc.
" 1 "Method is put into prologue behavior device (19 five equilibriums are divided in the bottom surface of helping to effect a compromise for diameter 30cm, the high 20cm of perisporium) with mice, and the record mice climbed the lattice number of times in 5 minutes; Administration in the 20th day used immobilization with adhesive tape in the stand edge mouse tail after 30 minutes, and the mice head is hung downwards.Record not when mice is movable occurs starting stopwatch when motionless, the motionless time of mice in the record accumulative total 6min, adopts relatively each group difference situation of Student ' s t test.
Result of the test:
1. to the influence of mice autonomic activities
The results are shown in Table 1, from the result as seen, amitriptyline (14mg/kg) group mice climbed the lattice number of times obviously than control group mice few (P＜0.05) in 5 minutes.Yushu Jiaonang (0.3g/kg, 0.6g/kg, 1.2g/kg) group mice climbs the lattice number of times in 5 minutes and control group mice compares no significant difference (P＞0.05).
Table 1 Yushu Jiaonang is to the influence of mice autonomic activities (X ± S)
| Group | Dosage (g/kg) | Number of animals (only) | Climb lattice number of times (5min) |
| Matched group Yushu Jiaonang group amitriptyline group | - 0.3 0.6 1.2 14mg | 10 10 10 10 10 | 220.6±54.84 212.3±52.28 199.8±39.52 205.5±57.59 159.3±52.94 ※ |
Annotate: compare with matched group
※P＜0.05
※ ※P＜0.01.
2. to the influence of mice dead time
The results are shown in Table 2, from the result as seen, Yushu Jiaonang (0.3g/kg, 0.6g/kg, 1.2g/kg) the group mice dead time is all than control group mice short (P＜0.05 or P＜0.01).
Table 2 Yushu Jiaonang is to the influence of mice dead time (X ± S)
| Group | Dosage (g/kg) | Number of animals (only) | Dead time (S) |
| Matched group Yushu Jiaonang group amitriptyline group | - 0.3 0.6 1.2 14mg | 10 10 10 10 10 | 130.1±15.59 90.9±30.78 ※※ 110.9±22.22 ※ 104.4±24.32 ※ 89.3±26.09 ※※ |
Annotate: compare with matched group
※P＜0.05
※ ※P＜0.01.
Conclusion:
This result of the test shows that Yushu Jiaonang (0.3g/kg, 0.6g/kg, 1.2g/kg) can obviously shorten the mouse tail suspension dead time, has certain antidepressant effect.
Two, to the influence of mice forced swimming
Test objective: observe the influence of Yushu Jiaonang, to estimate its antidepressant effect to the mice forced swimming.
Test material:
Medicine: Yushu Jiaonang extract dry powder (9.35g crude drug/g dry powder), positive element medicine technology development center provides during by sky, Beijing, lot number 20021211, it is standby to be made into the suspension of desired concn with 0.5% sodium carboxymethyl cellulose during use; Amitriptyline hydrochloride tablet (25mg), Hunan Dongting Pharmaceutical Co., Ltd., lot number 020125, it is standby to be made into the suspension of desired concn with 0.5% sodium carboxymethyl cellulose during use.
Animal: Kunming mouse (secondary), body weight 18--22g, male, the effluent north laboratory animal department of the Chinese Academy of Sciences of medical university provides, and the quality certification number is No. the 04056th, the moving word of doctor.
Test method:
Mice is divided into 5 groups at random, every group 10, be respectively matched group, Yushu Jiaonang low dose group (0.3g/kg, be equivalent to 5 times of the clinical consumption of people), dosage group (0.6g/kg in the Yushu Jiaonang, be equivalent to 10 times of the clinical consumption of people), Yushu Jiaonang high dose group (1.2g/kg, be equivalent to 20 times of the clinical consumption of people) and positive drug amitriptyline group (14mg/kg is equivalent to 10 times of the clinical consumption of people).Administration group gastric infusion every day once, capacity is the 0.2ml/10g body weight, matched group waits the capacity distilled water, successive administration 20 days, administration in the 19th day is after 30 minutes, with reference to Soubrie etc.
" 1 "Method is put into prologue behavior device (19 five equilibriums are divided in the bottom surface of helping to effect a compromise for diameter 30cm, the high 20cm of perisporium) with mice, and the record mice climbed the lattice number of times in 5 minutes; Administration in the 20th day is after 30 minutes, with reference to Xu Shuyun etc.
" 2 "Method, mice is put into high 30cm, in the cylindrical glass cylinder of diameter 18cm, depth of water 10cm, 23 ℃～25 ℃ of water temperatures, mice is inserted the 2min that swims in the water, and (motionless state: mice stops to struggle or being floating state in water to begin behind the observed and recorded in the 4min accumulative total dead time immediately, only expose the nostril and keep breathing, extremity paddling once in a while are unlikely to sink to keep health).Adopt relatively each group difference situation of Student ' s t test.
Result of the test:
1. to the influence of mice autonomic activities
The results are shown in Table 3, from the result as seen, amitriptyline (14mg/kg) group mice climbed the lattice number of times obviously than control group mice few (P＜0.01) in 5 minutes.Yushu Jiaonang (0.3g/kg, 0.6g/kg, 1.2g/kg) group mice climbs the lattice number of times in 5 minutes and control group mice compares no significant difference (P＞0.05).
Table 3 Yushu Jiaonang is to the influence of mice autonomic activities (X ± SD)
| Group | Dosage (g/kg) | Number of animals (only) | Climb lattice number of times (5min) |
| Matched group Yushu Jiaonang group amitriptyline group | - 0.3 0.6 1.2 14mg | 10 10 10 10 10 | 230.0±42.58 232.0±48.80 243.2±45.46 220.8±50.12 163.2±43.14 ※※ |
Annotate: compare with matched group
※P＜0.05
※ ※P＜0.01.
2. to the influence of mice dead time
The results are shown in Table 4, from the result as seen, Yushu Jiaonang (0.3g/kg, 0.6g/kg, 1.2g/kg) the group mice dead time is all than control group mice short (P＜0.01).
Table 4 Yushu Jiaonang is to the influence that forces the mice non-swimming time (X ± SD)
| Group | Dosage (g/kg) | Number of animals (only) | Dead time (S) |
| Matched group Yushu Jiaonang group amitriptyline group | - 0.3 0.6 1.2 14mg | 10 10 10 10 10 | 167.3±23.24 99.4±28.36 ※※ 96.5±27.09 ※※ 91.3±21.59 ※※ 89.0±20.27 ※※ |
Annotate: compare with matched group
※P＜0.05
※ ※P＜0.01.
Conclusion: this result of the test shows: Yushu Jiaonang (0.3g/kg, 0.6g/kg, 1.2g/kg) can obviously shorten the dead time of forced swimming mice, has certain antidepressant effect.
Three, to forcing the influence of rats'swimming
Test objective: observe the influence of Yushu Jiaonang, to estimate its antidepressant effect to the rat forced swimming.
Test material:
Medicine: Yushu Jiaonang extract dry powder (9.35g crude drug/g dry powder), positive element medicine technology development center provides during by sky, Beijing, lot number 20021211, it is standby to be made into the suspension of desired concn with 0.5% sodium carboxymethyl cellulose during use; Amitriptyline hydrochloride tablet (25mg), Hunan Dongting Pharmaceutical Co., Ltd., lot number 020125, it is standby to be made into the suspension of desired concn with 0.5% sodium carboxymethyl cellulose during use.
Animal: SD rat (secondary), body weight 160--170g, male, the effluent north laboratory animal department of the Chinese Academy of Sciences of medical university provides, and the quality certification number is No. the 04057th, the moving word of doctor.
Test method:
Rat is divided into 5 groups at random, every group 10, be respectively matched group, Yushu Jiaonang low dose group (0.2g/kg, be equivalent to 3.5 times of the clinical consumption of people), dosage group (0.4g/kg in the Yushu Jiaonang, be equivalent to 7 times of the clinical consumption of people), Yushu Jiaonang high dose group (0.8g/kg, be equivalent to 14 times of the clinical consumption of people) and positive drug amitriptyline group (10mg/kg is equivalent to 7 times of the clinical consumption of people).Administration group gastric infusion every day once, capacity is the 1.0ml/100g body weight, matched group waits the capacity distilled water, successive administration 20 days, administration in the 19th day is after 30 minutes, with reference to Xu Shuyun etc.
" 3 "Method, with rat put into prologue behavior device (wooden (-packing) case 100 * 100 * 50cm, 25 grids 20 * 20cm) are divided in the bottom surface, the record rat climbs the lattice number of times in 5 minutes; Administration in the 20th day is after 30 minutes, with reference to Xu Shuyun etc.
" 2 "Method, rat is put into the cylindrical glass cylinder of high 40cm, diameter 18cm, depth of water 18cm, 23 ℃～25 ℃ of water temperatures, the accumulative total dead time in the record 5min, (motionless state: rat stopped to struggle or being floating state in water, only expose the nostril and keep breathing, extremity paddling once in a while are unlikely to sink to keep health).Adopt relatively each group difference situation of Student ' s t test.
Result of the test:
1. to the influence of rat autonomic activities
The results are shown in Table 5, from the result as seen, amitriptyline (10mg/kg) group mice climbed the lattice number of times obviously than control group mice few (P＜0.05) in 5 minutes.Yushu Jiaonang (0.2g/kg, 0.4g/kg, 0.8g/kg) group mice climbs the lattice number of times in 5 minutes and control group mice compares no significant difference (P＞0.05).
Table 5 Yushu Jiaonang is to the influence of rat autonomic activities (X ± SD)
| Group | Dosage (g/kg) | Number of animals (only) | Climb lattice number of times (5min) |
| Matched group Yushu Jiaonang group | - 0.2 0.4 | 10 10 10 | 25.7±9.48 27.7±8.18 26.9±9.68 |
| The amitriptyline group | 0.8 10mg | 10 10 | 27.3±10.18 14.1±9.18 ※ |
Annotate: compare with matched group
※P＜0.05
※ ※P＜0.01.
2. to the influence of rat dead time
The results are shown in Table 6, from the result as seen, Yushu Jiaonang (0.2g/kg, 0.4g/kg, 0.8g/kg) the group rat dead time is all than control rats short (P＜0.01).
Table 6 Yushu Jiaonang is to the influence that forces the rats'swimming dead time (X ± SD)
| Group | Dosage (g/kg) | Number of animals (only) | Dead time (S) |
| Matched group Yushu Jiaonang group amitriptyline group | - 0.2 0.4 0.8 10mg | 10 10 10 10 10 | 110.9±14.37 74.9±13.16 ※※ 63.4±13.23 ※※ 60.8±11.40 ※※ 50.6±13.34 ※※ |
Annotate: compare with matched group
※P＜0.05
※ ※P＜0.01.
Four, reserpine is caused the influence of mice blepharoptosis.
Test objective:
Observe Yushu Jiaonang causes the mice blepharoptosis to reserpine influence.
Test material:
Medicine: Yushu Jiaonang extract dry powder (9.35g crude drug/g dry powder), positive element medicine technology development center provides during sky, Beijing, lot number 20021211, it is standby to be made into the suspension of desired concn with 0.5% sodium carboxymethyl cellulose during use; Amitriptyline hydrochloride tablet (25mg/ sheet), Hunan Dongting Pharmaceutical Co., Ltd., lot number 020125, it is standby to be made into the suspension of desired concn with 0.5% sodium carboxymethyl cellulose during use; Reserpine injection (1mg/ml), red flag pharmaceutical factory of Shanghai Medical Univ, lot number 020706.
Animal: Kunming mouse (secondary), body weight 18-22g, male, the effluent north laboratory animal department of the Chinese Academy of Sciences of medical university provides, and the quality certification number is 04056.
Test method:
Mice is divided into 6 groups at random, every group 10, be respectively normal control group, model control group, Yushu Jiaonang low dose group (0.3g/kg, be equivalent to 5 times of the clinical consumption of people), dosage group (0.6g/kg in the Yushu Jiaonang, be equivalent to 10 times of the clinical consumption of people), Yushu Jiaonang high dose group (1.2g/kg, be equivalent to 20 times of the clinical consumption of people) and positive drug amitriptyline group (14mg/kg is equivalent to 10 times of the clinical consumption of people).Administration group gastric infusion every day once, capacity is the 0.2ml/10g body weight, normal control group and model control group wait the capacity distilled water, successive administration 14 days, the last administration is after 30 minutes, with reference to Xu Shuyun etc.
" 4 "Method, each organizes respectively tail vein injection reserpine injection 5mg/kg of mice, observes mice blepharoptosis situation after 1 hour, and marks standards of grading by following standard: full cut-off, 4 minutes; Closed 3/4,3 fen; Closed 1/2,2 fen; Closed 1/4,1 fen; Open 0 fen entirely.Adopt relatively each group difference situation of Student ' s t test.
Result of the test:
The results are shown in Table 7, from the result as seen, the scoring of Yushu Jiaonang (0.3g/kg, 0.6g/kg, 1.2g/kg) group mice blepharoptosis is all than control group mice low (P＜0.01).
Table 7 Yushu Jiaonang causes the influence (X ± SD) of mice blepharoptosis to reserpine
| Group | Dosage (g/kg) | Number of animals (only) | Score value |
| Matched group model control group Yushu Jiaonang group amitriptyline group | -- -- 0.3 0.6 1.2 14mg | 10 10 10 10 10 10 | 0.0±0.0 ※※ 3.8±0.42 2.4±0.52 ※※ 2.3±0.48 ※※ 2.2±0.42 ※※ 1.7±0.67 ※※ |
Annotate: compare with model control group
※P＜0.05
※ ※P＜0.01.
Conclusion: this result of the test shows: Yushu Jiaonang (0.3g/kg, 0.6g/kg, 1.2g/kg) can obviously be alleviated reserpine and cause mice blepharoptosis state.
Five, reserpine is caused the influence that mouse temperature reduces.
Test objective:
Observe Yushu Jiaonang reserpine is caused the influence that mouse temperature reduces.
Test material:
Medicine: Yushu Jiaonang extract dry powder (9.35g crude drug/g dry powder), positive element medicine technology development center provides during sky, Beijing, lot number 20021211, it is standby to be made into the suspension of desired concn with 0.5% sodium carboxymethyl cellulose during use; Amitriptyline hydrochloride tablet (25mg), Hunan Dongting Pharmaceutical Co., Ltd., lot number 020125, it is standby to be made into the suspension of desired concn with 0.5% sodium carboxymethyl cellulose during use; Reserpine injection (1mg/ml), red flag pharmaceutical factory of Shanghai Medical Univ, lot number 020706.
Animal: Kunming mouse (secondary), body weight 18-20g, male and female half and half, the effluent north laboratory animal department of the Chinese Academy of Sciences of medical university provides, and the quality certification number is 04056.
Instrument: MC-3B computer numeral formula clinical thermometer, Omron (Dalian) company limited.
Test method:
With reference to Xu Shuyun etc.
" 4 "Method, mice is divided into 6 groups at random, every group 10, be respectively normal control group, model control group, Yushu Jiaonang low dose group (0.3g/kg, be equivalent to 5 times of the clinical consumption of people), dosage group (0.6g/kg in the Yushu Jiaonang, be equivalent to 10 times of the clinical consumption of people), Yushu Jiaonang high dose group (1.2g/kg is equivalent to 20 times of the clinical consumption of people) and positive drug amitriptyline group (14mg/kg is equivalent to 10 times of the clinical consumption of people).Administration group gastric infusion every day once, capacity is the 0.2ml/10g body weight, normal control group and model control group wait the capacity distilled water, successive administration 14 days, last administration were at first measured the basal body temperature of respectively organizing mice after 30 minutes, survey altogether 3 times at every turn, ask its average.Mice tail vein injection reserpine injection 2.5mg/kg respectively then, and measured mice anus temperature in back 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours in injection, adopt relatively each group difference situation of Student ' s t test.Result of the test:
The results are shown in Table 8, table 9, from the result as seen, Yushu Jiaonang (0.3g/kg, 0.6g/kg, 1.2g/kg) group mice behind the injection reserpine 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours each time point body temperature all than model control group mice height (P＜0.05 or P＜0.01).
Table 8 pair reserpine causes the influence that mouse temperature reduces (X ± S)
| Group | Dosage (g/kg) | Number of animals (only) | Different time points body temperature (℃) | |||
| 0h | 1h | 2h | 3h | |||
| Normal control group model matched group Yushu Jiaonang | ---- ---- 0.3 0.6 1.2 | 10 10 10 10 10 | 38.4±0.27 ※※ 38.4±0.26 38.4±0.24 38.5±0.20 38.4±0.23 | 38.5±0.24 ※※ 36.3±0.54 37.3±0.46 ※※ 37.9±0.27 ※※ 37.6±0.65 ※※ | 38.4±0.22 ※※ 36.2±0.60 37.1±0.27 ※※ 37.5±0.53 ※ 37.4±0.63 ※ | 38.5±0.26 ※※ 35.8±0.80 37.0±0.43 ※※ 37.2±0.44 ※※ 37.2±0.66 ※※ |
| The amitriptyline group | 14mg | 10 | 38.5±0.28 | 37.4±0.50 ※※ | 37.1±0.58 ※※ | 36.8±0.54 ※※ |
Compare with model control group
※P＜0.05
※ ※P＜0.01
Table 9 pair reserpine causes the influence that mouse temperature reduces (X ± S)
| Group | Dosage (g/kg) | Number of animals (only) | Different time points body temperature (℃) | ||
| 4h | 5h | 6h | |||
| Normal control group model matched group Yushu Jiaonang amitriptyline group | ---- ---- 0.3 0.6 1.2 14mg | 10 10 10 10 10 10 | 38.4±0.25 ※※ 35.8±0.65 36.9±0.43 ※※ 36.9±0.42 ※※ 36.7±0.60 ※※ 36.5±0.47 ※※ | 38.5±0.16 ※※ 35.7±0.76 36.4±0.42 ※ 36.6±0.42 ※※ 36.6±0.57 ※※ 36.4±0.60 ※ | 38.5±0.31 ※※ 35.3±1.02 36.3±0.49 ※ 36.4±0.51 ※※ 36.1±0.57 ※ 35.8±0.83 |
Compare with model control group
※P＜0.05
※ ※P＜0.01
Pharmacodynamic test of active extract proves: continuous 20 days gastric infusions of Yushu Jiaonang (0.3g/kg, 0.6g/kg, 1.2g/kg) can shorten the dead time of hanging the tail test mice; Can significantly shorten the dead time of mice forced swimming, mice autonomic activities number of times is not had obvious influence; Yushu Jiaonang (0.2g/kg, 0.4g/kg, 0.8g/kg) can obviously shorten the dead time of rat forced swimming, and rat autonomic activities number of times is not also had obvious influence; Continuous 14 days gastric infusions of Yushu Jiaonang (0.3g/kg, 0.6g/kg, 1.2g/kg) can obviously be alleviated reserpine and cause mice blepharoptosis state; Can resist reserpine and cause the mouse temperature reduction, have antidepressant effect.
The specific embodiment:
Further specify the present invention by the following examples.
Embodiment 1
Prescription:
Radix Paeoniae Alba 572g Herba Hyperici Monogyni 572g Radix Et Caulis Acanthopanacis Senticosi 357.5g Fructus Schisandrae Chinensis 357.5g
Cortex Albiziae 357.5g Radix Polygalae 357.5g Radix Morindae Officinalis 357.5g Fructus Tribuli 357.5g
Method for making:
More than eight flavors, Herba Hyperici Monogyni, Radix Et Caulis Acanthopanacis Senticosi, Fructus Schisandrae Chinensis three flavors add 6 times of amount 65% alcohol reflux secondaries, each 2 hours, merge extractive liquid, filtered, filtrate recycling ethanol is concentrated into relative density 1.10～1.12 (60 ℃); The medicinal residues and the Radix Paeoniae Alba, Cortex Albiziae, Radix Polygalae, Radix Morindae Officinalis, the Fructus Tribuli five tastes add 6 times of water gagings and decoct 2 times, and each 2 hours, collecting decoction, filter, filtrate is concentrated into relative density 1.20～1.22 (60 ℃), adds ethanol and makes and contain the alcohol amount and reach 50%, standing over night filters filtrate recycling ethanol, merge with above-mentioned ethanol extraction concentrated solution, be concentrated into relative density 1.10～1.12 (60 ℃), the adding microcrystalline Cellulose is an amount of, be spray dried to fine powder, sieve, incapsulate, make 1000, promptly.
Embodiment 2
Prescription:
Radix Paeoniae Alba 286g Herba Hyperici Monogyni 286g Radix Et Caulis Acanthopanacis Senticosi 179g Fructus Schisandrae Chinensis 179g
Cortex Albiziae 179g Radix Polygalae 179g Radix Morindae Officinalis 179g Fructus Tribuli 179g
Method for making:
More than eight flavors, Herba Hyperici Monogyni, Radix Et Caulis Acanthopanacis Senticosi, Fructus Schisandrae Chinensis three flavors add 6 times of amount 65% alcohol reflux secondaries, each 2 hours, merge extractive liquid, filtered, filtrate recycling ethanol is concentrated into relative density 1.10～1.12 (60 ℃); The medicinal residues and the Radix Paeoniae Alba, Cortex Albiziae, Radix Polygalae, Radix Morindae Officinalis, the Fructus Tribuli five tastes add 6 times of water gagings and decoct 2 times, and each 2 hours, collecting decoction, filter, filtrate is concentrated into relative density 1.20～1.22 (60 ℃), adds ethanol and makes and contain the alcohol amount and reach 50%, standing over night filters filtrate recycling ethanol, merge with above-mentioned ethanol extraction concentrated solution, be concentrated into relative density 1.10～1.12 (60 ℃), the adding microcrystalline Cellulose is an amount of, be spray dried to fine powder, sieve, incapsulate, make 1000, promptly.
Embodiment 3
Prescription:
Radix Paeoniae Alba 1144g Herba Hyperici Monogyni 1144g Radix Et Caulis Acanthopanacis Senticosi 715g Fructus Schisandrae Chinensis 715g
Cortex Albiziae 715g Radix Polygalae 715g Radix Morindae Officinalis 715g Fructus Tribuli 715g
Method for making:
More than eight flavors, Herba Hyperici Monogyni, Radix Et Caulis Acanthopanacis Senticosi, Fructus Schisandrae Chinensis three flavors add 6 times of amount 65% alcohol reflux secondaries, each 2 hours, merge extractive liquid, filtered, filtrate recycling ethanol is concentrated into relative density 1.10～1.12 (60 ℃); The medicinal residues and the Radix Paeoniae Alba, Cortex Albiziae, Radix Polygalae, Radix Morindae Officinalis, the Fructus Tribuli five tastes add 6 times of water gagings and decoct 2 times, and each 2 hours, collecting decoction, filter, filtrate is concentrated into relative density 1.20～1.22 (60 ℃), adds ethanol and makes and contain the alcohol amount and reach 50%, standing over night filters filtrate recycling ethanol, merge with above-mentioned ethanol extraction concentrated solution, be concentrated into relative density 1.10～1.12 (60 ℃), the adding microcrystalline Cellulose is an amount of, be spray dried to fine powder, sieve, incapsulate, make 1000, promptly.
Embodiment 4
Prescription:
Radix Paeoniae Alba 572g Herba Hyperici Monogyni 572g Radix Et Caulis Acanthopanacis Senticosi 357.5g Fructus Schisandrae Chinensis 357.5g
Cortex Albiziae 357.5g Radix Polygalae 357.5g Radix Morindae Officinalis 357.5g Fructus Tribuli 357.5g
Method for making:
More than eight flavors, Herba Hyperici Monogyni, Radix Et Caulis Acanthopanacis Senticosi, Fructus Schisandrae Chinensis three flavors add 6 times of amount 65% alcohol reflux secondaries, each 2 hours, merge extractive liquid, filtered, filtrate recycling ethanol is concentrated into relative density 1.10～1.12 (60 ℃); The medicinal residues and the Radix Paeoniae Alba, Cortex Albiziae, Radix Polygalae, Radix Morindae Officinalis, the Fructus Tribuli five tastes add 6 times of water gagings and decoct 2 times, each 2 hours, collecting decoction, filter, filtrate is concentrated into relative density 1.20～1.22 (60 ℃), adds ethanol and makes and contain alcohol amount and reach 50%, standing over night, filter, filtrate recycling ethanol merges with above-mentioned ethanol extraction concentrated solution, is concentrated into relative density 1.10～1.12 (60 ℃), it is an amount of to add microcrystalline Cellulose, be spray dried to fine powder, it is an amount of to add starch, wetting agent, magnesium stearate, mix homogeneously, tabletting is made 1000 in tablet.
Embodiment 5
Prescription:
Radix Paeoniae Alba 572g Herba Hyperici Monogyni 572g Radix Et Caulis Acanthopanacis Senticosi 357.5g Fructus Schisandrae Chinensis 357.5g
Cortex Albiziae 357.5g Radix Polygalae 357.5g Radix Morindae Officinalis 357.5g Fructus Tribuli 357.5g
Method for making:
More than eight flavors, Herba Hyperici Monogyni, Radix Et Caulis Acanthopanacis Senticosi, Fructus Schisandrae Chinensis three flavors add 6 times of amount 65% alcohol reflux secondaries, each 2 hours, merge extractive liquid, filtered, filtrate recycling ethanol is concentrated into relative density 1.10～1.12 (60 ℃); The medicinal residues and the Radix Paeoniae Alba, Cortex Albiziae, Radix Polygalae, Radix Morindae Officinalis, the Fructus Tribuli five tastes add 6 times of water gagings and decoct 2 times, and each 2 hours, collecting decoction, filter, filtrate is concentrated into relative density 1.20～1.22 (60 ℃), adds ethanol and makes and contain the alcohol amount and reach 50%, standing over night filters filtrate recycling ethanol, merge with above-mentioned ethanol extraction concentrated solution, be concentrated into relative density 1.10～1.12 (60 ℃), it is an amount of to add microcrystalline Cellulose, sucrose, is spray dried to fine powder, the 1000g granule is made in pack.
Embodiment 6
Prescription:
Radix Paeoniae Alba 763g Herba Hyperici Monogyni 763g Radix Et Caulis Acanthopanacis Senticosi 477g Fructus Schisandrae Chinensis 477g
Cortex Albiziae 477g Radix Polygalae 477g Radix Morindae Officinalis 477g Fructus Tribuli 477g
Method for making:
More than eight flavors, Herba Hyperici Monogyni, Radix Et Caulis Acanthopanacis Senticosi, Fructus Schisandrae Chinensis three flavors add 6 times of amount 65% alcohol reflux secondaries, each 2 hours, merge extractive liquid, filtered, filtrate recycling ethanol is concentrated into relative density 1.10～1.12 (60 ℃); The medicinal residues and the Radix Paeoniae Alba, Cortex Albiziae, Radix Polygalae, Radix Morindae Officinalis, the Fructus Tribuli five tastes add 6 times of water gagings and decoct 2 times, and each 2 hours, collecting decoction, filter, filtrate is concentrated into relative density 1.20～1.22 (60 ℃), adds ethanol and makes and contain the alcohol amount and reach 50%, standing over night filters filtrate recycling ethanol, merge with above-mentioned ethanol extraction concentrated solution, be concentrated into relative density 1.10～1.12 (60 ℃), the adding microcrystalline Cellulose is an amount of, be spray dried to fine powder, sieve, incapsulate, make 1000, promptly.
Embodiment 7
Prescription:
Radix Paeoniae Alba 429g Herba Hyperici Monogyni 429g Radix Et Caulis Acanthopanacis Senticosi 268g Fructus Schisandrae Chinensis 268-g
Cortex Albiziae 268g Radix Polygalae 268g Radix Morindae Officinalis 268g Fructus Tribuli 268g
Method for making:
More than eight flavors, Herba Hyperici Monogyni, Radix Et Caulis Acanthopanacis Senticosi, Fructus Schisandrae Chinensis three flavors add 6 times of amount 65% alcohol reflux secondaries, each 2 hours, merge extractive liquid, filtered, filtrate recycling ethanol is concentrated into relative density 1.10～1.12 (60 ℃); The medicinal residues and the Radix Paeoniae Alba, Cortex Albiziae, Radix Polygalae, Radix Morindae Officinalis, the Fructus Tribuli five tastes add 6 times of water gagings and decoct 2 times, and each 2 hours, collecting decoction, filter, filtrate is concentrated into relative density 1.20～1.22 (60 ℃), adds ethanol and makes and contain the alcohol amount and reach 50%, standing over night filters filtrate recycling ethanol, merge with above-mentioned ethanol extraction concentrated solution, be concentrated into relative density 1.10～1.12 (60 ℃), the adding microcrystalline Cellulose is an amount of, be spray dried to fine powder, sieve, incapsulate, make 1000, promptly.
Claims (10)
1, a kind of antidepressant Chinese medicine preparation is characterized in that, raw material composition and the weight proportion thereof of making this pharmaceutically active ingredient are:
Radix Paeoniae Alba 286-1144 part Herba Hyperici Monogyni 286-1144 part Radix Et Caulis Acanthopanacis Senticosi 179-715 part Fructus Schisandrae Chinensis 179-715 part
Cortex Albiziae 179-715 part Radix Polygalae 179-715 part Radix Morindae Officinalis 179-715 part Fructus Tribuli 179-715 part.
2, the Chinese medicine preparation of claim 1 is characterized in that, raw material composition and the weight proportion thereof of making this pharmaceutically active ingredient are:
Radix Paeoniae Alba 429-763 part Herba Hyperici Monogyni 429-763 part Radix Et Caulis Acanthopanacis Senticosi 268-477 part Fructus Schisandrae Chinensis 268-477 part
Cortex Albiziae 268-477 part Radix Polygalae 268-477 part Radix Morindae Officinalis 268-477 part Fructus Tribuli 268-477 part.
3, the Chinese medicine preparation of claim 1 is characterized in that, raw material composition and the weight proportion thereof of making this pharmaceutically active ingredient are:
357.5 parts of 357.5 parts of Fructus Schisandrae Chinensis of 572 parts of Radix Et Caulis Acanthopanacis Senticosis of 572 parts of Herba Hyperici Monogynis of the Radix Paeoniae Alba
357.5 parts of 357.5 portions of Fructus Tribulis of 357.5 parts of Radix Morindae Officinaliss of 357.5 parts of Radix Polygalaes of Cortex Albiziae.
4, the Chinese medicine preparation of claim 1 is characterized in that, is selected from tablet, capsule, oral liquid, granule, pill, powder, unguentum, sublimed preparation, suspensoid, powder, solution, suppository, unguentum, drop pill or patch.
5, the Chinese medicine preparation of claim 1 is a capsule.
6, the preparation method of the Chinese medicine preparation of claim 1 is characterized in that, the process following steps:
Herba Hyperici Monogyni, Radix Et Caulis Acanthopanacis Senticosi, Fructus Schisandrae Chinensis three flavors add alcohol reflux, and extracting solution filters, and filtrate recycling ethanol concentrates; The medicinal residues and the Radix Paeoniae Alba, Cortex Albiziae, Radix Polygalae, Radix Morindae Officinalis, the Fructus Tribuli five tastes decoct with water, decocting liquid filters, filtrate concentrates, and adds ethanol, standing over night, filter, filtrate recycling ethanol merges with above-mentioned ethanol extraction concentrated solution, concentrates, obtain active constituents of medicine, this composition is mixed and made into Chinese medicine preparation of the present invention separately or with the medicine acceptable carrier.
7, the preparation method of the Chinese medicine preparation of claim 5 is characterized in that, the process following steps:
Herba Hyperici Monogyni, Radix Et Caulis Acanthopanacis Senticosi, Fructus Schisandrae Chinensis three flavors add 6 times of amount 65% alcohol reflux secondaries, and each 2 hours, merge extractive liquid, filtered, and filtrate recycling ethanol is concentrated into relative density 1.10～1.12; The medicinal residues and the Radix Paeoniae Alba, Cortex Albiziae, Radix Polygalae, Radix Morindae Officinalis, the Fructus Tribuli five tastes add 6 times of water gagings and decoct 2 times, and each 2 hours, collecting decoction, filter, filtrate is concentrated into relative density 1.20～1.22, adds ethanol and makes and contain the alcohol amount and reach 50%, standing over night filters filtrate recycling ethanol, merge with above-mentioned ethanol extraction concentrated solution, be concentrated into relative density 1.10～1.12, the adding microcrystalline Cellulose is an amount of, be spray dried to fine powder, sieve, incapsulate, make 1000, promptly.
8, the preparation method of claim 6 is characterized in that, the described alcohol reflux that adds is for adding 6 times of amount 65% alcohol reflux secondaries, each 2 hours.
9, the preparation method of claim 6 is characterized in that, described decocting with water to adding 6 times of water gagings decocts each 2 hours 2 times.
10, the application of the pharmaceutical preparation of claim 1 in the antidepressant medicine of preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510055375 CN1282470C (en) | 2005-03-21 | 2005-03-21 | Traditional Chinese medicine for anti depression |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510055375 CN1282470C (en) | 2005-03-21 | 2005-03-21 | Traditional Chinese medicine for anti depression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1686337A CN1686337A (en) | 2005-10-26 |
| CN1282470C true CN1282470C (en) | 2006-11-01 |
Family
ID=35304379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510055375 Expired - Fee Related CN1282470C (en) | 2005-03-21 | 2005-03-21 | Traditional Chinese medicine for anti depression |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1282470C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101658659A (en) * | 2009-05-20 | 2010-03-03 | 北京国奥健康科技研究院 | Chinese herba preparation for treating anxiety disorder |
| CN105194514A (en) * | 2015-10-27 | 2015-12-30 | 青岛海之源智能技术有限公司 | Compound agomelatine sustained-release capsule and preparation method thereof |
-
2005
- 2005-03-21 CN CN 200510055375 patent/CN1282470C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1686337A (en) | 2005-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101032560A (en) | Chinese medicine composition for treating somnipathy and preparing method thereof | |
| CN1840166A (en) | Modern Chinese medicinal oral liquid of 'Wen Dan Tang' and preparation method thereof | |
| CN1915399A (en) | Preparation for treating high blood pressure, high blood fat, obesity, and climacteric syndrome, and preparation method | |
| CN1947757A (en) | Leave of glutinous rehmannia extractive, its prepn. method and use, medicines prepd. with said extractives | |
| CN101032580A (en) | Medicine for treating rheumatic diseases | |
| CN1297291C (en) | Medicine for abstaining from drug addiction and its preparation | |
| CN1927331A (en) | Chinese medicine preparation for curing chronic heart failure | |
| CN1191082C (en) | Chinese medicinal composition for treating fatty liver and its preparation method | |
| CN1282470C (en) | Traditional Chinese medicine for anti depression | |
| CN1850255A (en) | Medicine composition and preparing method | |
| CN1232267C (en) | Compound plant medicine and its application | |
| CN1559495A (en) | Deer's fetus granular Chinese madicinal preparation and its production technology | |
| CN1686469A (en) | Medicament for treating coronary heart disease and its preparation method | |
| CN1232279C (en) | Antilipemic Chinese medicine | |
| CN1276775C (en) | Chinese traditional medicine for treating optical fundus hemorrhage and its preparing process | |
| CN1256143C (en) | Chinese medicinal composite preparation against virus | |
| CN1853688A (en) | Chinese medicinal preparation for treating heart cerebrovascular disease and ischemic apoplexia and making method thereof | |
| CN1309318C (en) | Body building nutrient | |
| CN1290566C (en) | Depression treating medicinal formulation and its preparation process | |
| CN1686302A (en) | Traditional Chinese medicine for treating non-alcoholic simple fatty liver and its preparation method | |
| CN1899581A (en) | Medicinal composition for treating qi stagnation and cold stasis stomach-ache and its preparing method and use | |
| CN100342901C (en) | Chinese medicinal composition for treating diabetes, its preparation method and use | |
| CN1227023C (en) | Drug for treating coronary heart disease, angina and preparation method | |
| CN1640436A (en) | Chinese medicine composition for treating menstrual period syndrome | |
| CN1651017A (en) | Medicinal composition for treating cervical vertebra disease and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: TIANJIN TASLY PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: TIANLI ZHENGYUAN MEDICINE TECHNOLOGY DEVELOPMENT CO., LTD., BEIJING Effective date: 20060217 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20060217 Address after: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Applicant after: Tianjin Tianshili Pharmaceutical Co., Ltd. Address before: 100070, room 1, building 2, 5358 Fu Heng street, Fengtai District Science Town, Beijing, China Applicant before: Tianli Zhengyuan Medicine Technology Development Co., Ltd., Beijing |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: TASLY PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: TIANJIN TASLY PHARM. CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Patentee after: Tasly Pharmaceutical Group Co., Ltd. Address before: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Patentee before: Tianjin Tianshili Pharmaceutical Co., Ltd. |
|
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: 300410 Tianjin city Beichen District Huaihe road and road intersection Dingjiang tianzhijiao Park forensic Center for Intellectual Property Department Patentee after: Tasly Pharmaceutical Group Limited by Share Ltd Address before: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Patentee before: Tasly Pharmaceutical Group Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20061101 Termination date: 20200321 |